New hope for Hard-to-Treat RET cancers: experimental pill enters human testing
NCT ID NCT05241834
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 30 times
Summary
This early-stage study tests an experimental pill called LOXO-260 in about 70 adults whose cancer has a specific RET gene change and has stopped responding to other targeted treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study lasts up to 2 years for each participant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Leon Berard
Lyon, 69008, France
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30329-5102, United States
-
Institut Gustave Roussy (Igr)
Villejuif, 94805, France
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Ohio State University Hospital
Columbus, Ohio, 43210-1257, United States
-
Sarah Cannon Cancer Center
Nashville, Tennessee, 37203, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
UCSF Medical Center at Mission Bay
San Francisco, California, 94158, United States
-
University of Chicago Medicine-Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27514, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.